RQ Bio reels in $115M to take long-acting flu prevention antiviral into clinic
Summary
RQ Bio has raised $115 million to move its long-acting flu prevention antiviral into the clinic. The financing gives the company capital to advance development and clinical testing of its lead program. This matters to software readers mainly as a life sciences company event rather than a software product announcement. The most relevant taxonomy fit is pharma and life sciences management, not a broad SaaS or ISV software category.
Funding
Amount
$115.0M
Total raised
Date
June 24, 2026
Announcement date
Investors
-
Lead investors
Company
-
Funded company
Classifications
industries
No industries detected
applications
No applications detected
AI Classifications
Labels
No AI classifications detected